Short answer
Altimmune, Inc. (ALT) filed an 8-K current report with the SEC on November 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 financial results announced for quarter ended September 30, 2026.
Altimmune, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 financial results announced for quarter ended September 30, 2026
- Investors should review Exhibit 99.1 for revenue, cash position, operating expenses and pipeline updates
Item EX-99.1 · Exhibit EX-99.1
- Cash, equivalents and investments $480M as of September 30, 2026, supporting continued late-stage clinical development
- PERFORMA Phase 3 MASH trial advancing, with 52-week topline data expected in 2029
- FDA End-of-Phase 2 meeting scheduled for December 2026, potentially defining AUD Phase 3 registrational requirements
- Quarterly R&D expense $27.0M, up from $15.0M, driven by PERFORMA and RESTORE trial activity
- Net loss $31.6M, or $0.15 per share, versus $19.0M, or $0.21 per share, in the prior-year quarter
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Altimmune, Inc. 8-K filings
Get the next ALT 8-K as it lands
Follow ALT for push alerts, or ask the research agent what this filing means.